The price of UBX dropped over 60% after the announcement of bad results of the study of UBX0101 (treatment for knees osteoarthritis). Despite these bad results, UNITY Biotechnology has great potential since they do not focus only on one study. For example, they work on UBX1325, a treatment focused on retinal disease. In the last announcement, they state that they have enough money to fund operations well into 2022.
Enter price: Market Price target: $15 or even more